Grant: Team: Human Immun.- LOI - Autoimmune diseases-digestive, kidney, pancreas, liver
University of Calgary
$20,000.00
Reducing Morbidity and Mortality in Inflammatory Bowel Disease by Targeting Intestinal Fibrosis
FY 2018-19
Summary
The prevalence of inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD) continues to increase with 1 in 150 Canadians being affected. Fibrostenotic disease (FSD) or scarring of the bowel results from abnormal recovery from inflammation resulting in deposition of connective tissue or scar tissue in the bowel wall. This leads to bowel stiffness and narrowing, resulting in; pain, bowel obstruction/blockage and perforation. 30% of CD patients develop FSD of which 70% will require surgery. At present we do not know whom with IBD will develop FSD and there are no medications that can prevent or treat FSD in IBD.
Myofibroblasts (MFB) are part of the normal structure of the bowel to maintain connective tissue but in CD they can cause FSD. It is thought that over-activation of MFB results in excess connective tissue deposition and FSD. Recently, a cell in the blood stream, called a fibrocyte (FC), has been implicated in fibrosis in the heart, kidney and lung. These FCs can migrate from the blood to the bowel and transform into MFBs. FCs have not been studied in IBD or intestinal fibrosis. We hypothesize that FCs play a critical role in the development of FSD in IBD.
The bacterial community in the intestine (microbiota) have been implicated in causing IBD and impacting disease severity. Recent studies suggest that specific microbiota patterns correlate with the development of FSD in IBD. We hypothesize that microbiota changes can alter the immune system and proteins in the blood stream leading to changes in FC number and function, resulting in FSD.
Our exciting preliminary data shows that peripheral blood FC number as well as RNA and protein expression patterns correlate with presence of FSD. Furthermore, we have identified new pathways and inhibitors that block activation of FCs.
These studies will greatly enhance our knowledge of the manner of developing FSD in IBD and will lead to new tools to prevent and treat FSD in all other organs.
Department
Program
Team: Human Immun.- LOI - Autoimmune diseases-digestive, kidney, pancreas, liver
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
396026
Name
Beck Paul L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Human Immunology Initiative - Research Teams
Projecttitle
Reducing Morbidity and Mortality in Inflammatory Bowel Disease by Targeting Intestinal Fibrosis
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Team: Human Immun.- LOI - Autoimmune diseases-digestive, kidney, pancreas, liver
Keyworddelim
Cellular Biology; Crohn'S Disease; Inflammation; Inflammatory Bowel Disease; Intestinal Fibrosis; Meta-Transcriptomics; Proteomics; Rna-Sequencing
Abstract
The prevalence of inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD) continues to increase with 1 in 150 Canadians being affected. Fibrostenotic disease (FSD) or scarring of the bowel results from abnormal recovery from inflammation resulting in deposition of connective tissue or scar tissue in the bowel wall. This leads to bowel stiffness and narrowing, resulting in; pain, bowel obstruction/blockage and perforation. 30% of CD patients develop FSD of which 70% will require surgery. At present we do not know whom with IBD will develop FSD and there are no medications that can prevent or treat FSD in IBD.
Myofibroblasts (MFB) are part of the normal structure of the bowel to maintain connective tissue but in CD they can cause FSD. It is thought that over-activation of MFB results in excess connective tissue deposition and FSD. Recently, a cell in the blood stream, called a fibrocyte (FC), has been implicated in fibrosis in the heart, kidney and lung. These FCs can migrate from the blood to the bowel and transform into MFBs. FCs have not been studied in IBD or intestinal fibrosis. We hypothesize that FCs play a critical role in the development of FSD in IBD.
The bacterial community in the intestine (microbiota) have been implicated in causing IBD and impacting disease severity. Recent studies suggest that specific microbiota patterns correlate with the development of FSD in IBD. We hypothesize that microbiota changes can alter the immune system and proteins in the blood stream leading to changes in FC number and function, resulting in FSD.
Our exciting preliminary data shows that peripheral blood FC number as well as RNA and protein expression patterns correlate with presence of FSD. Furthermore, we have identified new pathways and inhibitors that block activation of FCs.
These studies will greatly enhance our knowledge of the manner of developing FSD in IBD and will lead to new tools to prevent and treat FSD in all other organs.
Competitiondate
201810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beck, Paul L; Dufour, Antoine; Hirota, Simon A; Jijon, Humberto B; Lu, Cathy; Seow, Cynthia H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $20,000~ $0~